Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BetterLife (BETR) files patent for the invention of a novel subcutaneous implant to prevent diversion of LSD and other psychedelic drugs
  • Clinical trials of the implant to monitor LSD and psilocybin microdosing are ongoing
  • One potential issue is the possibility of a patient consuming a full psychedelic dose of psilocybin or LSD as opposed to the prescribed microdose
  • BetterLife’s invention has solved this problem by use of an implant administered by an outpatient procedure performed by a physician
  • BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products for the treatment of mental disorders
  • BetterLife Pharma Inc. (BETR) is down 9.59 per cent and is trading at C$0.66 at 2:24 pm ET

BetterLife (BETR) has filed for patent protection of a novel subcutaneous implant to prevent drug diversion of LSD and other psychedelic drugs.

Clinical trials of the implant to monitor LSD and psilocybin microdosing are ongoing.

Potential issues include the possibility of the patient consuming a full psychedelic dose of psilocybin or LSD as opposed to the prescribed microdose, or the resale of the drugs to someone other than the patient. 

BetterLife’s invention has solved this problem by the use of an implant administered by an outpatient procedure performed by a physician. 

The technical specification includes the option for a pulsatile release in accordance with current microdosed psychedelic protocols as well as an extended duration of release.

Ahmad Doroudian, CEO of BetterLife, commented,

“Controlled substances, including but not limited to psychedelic drugs such as LSD and psylocibin, have recently become of interest for the treatment of mental health disorders among other medical indications.”

“The application of our novel implantable subcutaneous product will enable widespread use of such drugs without the associated risks of unintentional misdosing or intentional diversion,” added Doroudian.

BetterLife’s novel implantable subcutaneous product allows for the administration of one or more drugs. It can be potentially used for extended-release or other controlled release needs.

In addition to overcoming the drug diversion issue, it will potentially greatly assist in reducing the burden on patients as well as associated healthcare costs for certain repeat dosing treatments.

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products for the treatment of mental disorders.

BetterLife Pharma Inc. (BETR) is down 9.59 per cent and is trading at C$0.66 at 2:24 pm ET.

More From The Market Herald
Levitee Labs - CEO, Pouya Farmand.

" Levitee Labs (CSE:LVT) partners with Adracare for addiction and mental health support

Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services.

" Cardiol Therapeutics (TSX:CRDL) expands phase II/III trial of CardiolRx

Cardiol Therapeutics (CRDL) is expanding its LANCER trial to include several hospital centers in Brazil, Mexico, and Canada.

" XORTX Therapeutics (CSE:XRX) closes public offering

XORTX Therapeutics (XRX) announced the closing of a US$12M public offering.

" Marvel Biosciences (TSXV:MRVL) updates the status of its MB-204 manufacturing efforts

Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.